BioPharmSignal logoBioPharmSignal

Biotech News

MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

MacroGenics (MGNX)MacroGenicsEarnings

Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform Realigned pipeline priorities by ending development of lorigerlimab in prostate cancer while continuing

Related news

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

View all latest news

MacroGenics

Antibody Engineering Company MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates. ADC Portfolio MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid...

Recent company news

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MGNXMacroGenics2026-08-11 20:05 EST

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MGNXMacroGenics2026-07-23 20:01 EST

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MGNXMacroGenics2026-07-02 13:25 EST

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MGNXMacroGenics2026-06-22 20:43 EST

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

Stock data

Close
4.10 USD
Market cap
257.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States